![Raquibul Hannan (@raquib_hannan) 's Twitter Profile](https://pbs.twimg.com/profile_images/1763019299516510208/qz1e0M7N_200x200.jpg)
Raquibul Hannan
@raquib_hannan
GU Radiation Oncologist and Physician/Scientist at UT Southwestern
ID: 1638659249155735552
22-03-2023 21:50:54
14 Tweet
89 Followers
82 Following
![Raquibul Hannan (@raquib_hannan) 's Twitter Profile Photo Raquibul Hannan (@raquib_hannan) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1763019299516510208/qz1e0M7N_200x200.jpg)
![Raquibul Hannan (@raquib_hannan) 's Twitter Profile Photo Raquibul Hannan (@raquib_hannan) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1763019299516510208/qz1e0M7N_200x200.jpg)
Excited to open phase 3 #clinicaltrial of #Stereotactic #Radiotherapy for #Oligometastatic #RenalCarcinoma (EA8211-SOAR), comparing systemic therapy vs. SAbR for mRCC patients w/ endpoints of OS & ≥Gr3 AE. ECOG-ACRIN Cancer Research Group NRG Oncology ASTRO KidneyCancerProgram UTSW Simmons Cancer Center tinyurl.com/yc8rrr7z
![Raquibul Hannan (@raquib_hannan) on Twitter photo Excited to open phase 3 #clinicaltrial of #Stereotactic #Radiotherapy for #Oligometastatic #RenalCarcinoma (EA8211-SOAR), comparing systemic therapy vs. SAbR for mRCC patients w/ endpoints of OS & ≥Gr3 AE. <a href="/eaonc/">ECOG-ACRIN Cancer Research Group</a> <a href="/NRGonc/">NRG Oncology</a> <a href="/ASTRO_org/">ASTRO</a> <a href="/KCPUTSW/">KidneyCancerProgram</a> <a href="/utswcancer/">UTSW Simmons Cancer Center</a>
tinyurl.com/yc8rrr7z Excited to open phase 3 #clinicaltrial of #Stereotactic #Radiotherapy for #Oligometastatic #RenalCarcinoma (EA8211-SOAR), comparing systemic therapy vs. SAbR for mRCC patients w/ endpoints of OS & ≥Gr3 AE. <a href="/eaonc/">ECOG-ACRIN Cancer Research Group</a> <a href="/NRGonc/">NRG Oncology</a> <a href="/ASTRO_org/">ASTRO</a> <a href="/KCPUTSW/">KidneyCancerProgram</a> <a href="/utswcancer/">UTSW Simmons Cancer Center</a>
tinyurl.com/yc8rrr7z](https://pbs.twimg.com/media/F5hBd-RX0AQveQ5.jpg)
![Shankar Siva (@_shankarsiva) 's Twitter Profile Photo Shankar Siva (@_shankarsiva) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1177357858255470593/avWaWpzG_200x200.jpg)
🧵4/ Median F/U=43months. 100% local control + cancer specific survival throughout the lifetime of the trial – i.e. no patient failed or died of cancer. Renal function decline similar to partial nephrectomy; baseline eGFR=60mls/min, ⬇️14.6mls/min post SABR. #ASTRO23 Kidney Cancer
![Shankar Siva (@_shankarsiva) on Twitter photo 🧵4/ Median F/U=43months. 100% local control + cancer specific survival throughout the lifetime of the trial – i.e. no patient failed or died of cancer. Renal function decline similar to partial nephrectomy; baseline eGFR=60mls/min, ⬇️14.6mls/min post SABR. #ASTRO23 <a href="/KidneyCancer/">Kidney Cancer</a> 🧵4/ Median F/U=43months. 100% local control + cancer specific survival throughout the lifetime of the trial – i.e. no patient failed or died of cancer. Renal function decline similar to partial nephrectomy; baseline eGFR=60mls/min, ⬇️14.6mls/min post SABR. #ASTRO23 <a href="/KidneyCancer/">Kidney Cancer</a>](https://pbs.twimg.com/media/F7Xva94bUAABlsm.jpg)
![UTSW Radiation Oncology (@utsw_radonc) 's Twitter Profile Photo UTSW Radiation Oncology (@utsw_radonc) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1067073443009425409/HWgKNzPS_200x200.jpg)
![UTSW Radiation Oncology (@utsw_radonc) 's Twitter Profile Photo UTSW Radiation Oncology (@utsw_radonc) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1067073443009425409/HWgKNzPS_200x200.jpg)